SGLT2 inhibitors are now recommended as cofirst-line therapy alongside RAS inhibitors in the majority of patients with CKD.16, 17, 18 Some patient populations were not included in pivotal trials, including patients with polycystic kidney disease, lupus nephritis, antinuclear cytoplasmic antibody (ANCA)-associated vasculitis, and those with a history of kidney transplantation, and as such, recommendations in these populations can vary. The gene discussed is SLC5A2; the disease is chronic kidney disease.